Latest News
Press Release
Sep 9, 2024
Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01
Topline data from a one-year interim analysis of the ongoing phase 2 trial show that 11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate 15 out of the 16 patients had reduction of their tumors (target lesions) The complete one-year dataset will be presented
Press Release
Sep 09, 2024
Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2
New pre-clinical data demonstrates that the novel EVX-B2 mRNA vaccine candidate triggers a targeted immune response The specific immune response leads to the elimination of the gonorrhea bacteria The data confirm that Evaxion’s AI-Immunology™ platform is delivery modality agnostic COPENHAGEN,
Press Release
August 14, 2024
Evaxion Announces Business Update and Second Quarter 2024 Financial Results
COPENHAGEN, Denmark, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces second quarter 2024 financial results.
Press Release
Aug 12, 2024
Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14
COPENHAGEN, Denmark, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its second quarter 2024 financial results on
Event
Sep 18, 2024 from 7:00 PM to 8:00 PM CEST
